Company News

Our products’ environmental performance is a core pillar of our commitment to protecting the planet. For several years, bioMérieux has been implementing a continuous improvement approach based on Life Cycle Assessments (LCAs) of our diagnostic solutions. The goal is to measure our products’ impact on the climate and environment across the entire value chain — from manufacturing and customer use to end-of-life management.

In line with our public health mission, bioMérieux and BioFire Defense, a bioMérieux company, are mobilizing Ebola diagnostics to support ongoing efforts related to the current Ebola outbreak in Africa.

In the ICU, minutes count — particularly for patients with sepsis, where a sudden drop in blood pressure can signal a dangerous turn. If care teams can see that change coming, even by a couple of hours, they can prepare, personalize treatment, and potentially prevent a crisis. That’s where interpretable, clinically grounded AI can help — turning routine hospital data into early warning signs.

bioMérieux announces an investment of more than one million Swiss Francs in Plair, a scale-up company offering a breakthrough solution for real-time microbial detection and air sampling. 

Respiratory symptoms send millions of people to emergency departments (EDs) every year. For clinicians, sorting through those symptoms quickly isn’t easy. For patients, that uncertainty can be stressful: long waits, unclear answers, and sometimes unnecessary treatments, including antibiotics that won’t help viral infections.